Listerian surgery, when the principle of aseptic operations had been established, but the exact means of preventing infection during surgery had not yet been mastered.
By and large, however, there was no general acceptance of either the trophoblastic theory or enzyme therapy (as there was for Listerian surgery). In fact, by the time Beard published The Enzyme Treatment of Cancer and its Scientific Basis 1 in 1911, this method of treatment had been almost universally abandoned. Many of Beard's last papers were devoted to the promotion of enzymes for other purposes, such as the treatment of malaria. But here too he was met with a wall of indifference. The watershed events of World War I caused enzyme therapy to be almost entirely forgotten. There were episodes of resurgence, but there was to be no continuous development of the field until the 1960s. However, there were a few individuals who carried on the tradition. Each faced an uphill battle in advocating a still unproven treatment in the face of growing medical intransigence. These are their stories.
Marshall William McDuffie, MD
In Beard's last published paper (1919) , he reported approvingly that Dr W. M. McDuffie of New York had introduced the use of intravenous injections of trypsin, and that preliminary results were encouraging. 2 Marshall William McDuffie, MD (1882-1945) was a prominent American homeopathic doctor and an attending surgeon at Metropolitan Hospital, New York. He was the son of a F or the first two decades of the 20th century, advocacy of the enzyme therapy of cancer was primarily the work of one man, John Beard, DSc (1858 -1924 . Beard was an embryologist at the University of Edinburgh who devised the trophoblastic theory of cancer, which provided the theoretical underpinnings for enzyme treatment. Beard and his collaborators made a determined effort to establish this mode of therapy, especially in the years 1905 to 1911. However, despite a brief flowering of international interest during that period, Beard's efforts came to naught.
Beard believed that the medical establishment of the time refused to accept an obviously effective treatment. However, a more plausible explanation is that despite a few spectacular successes, enzyme therapy (particularly with trypsin) more often than not was a failure. It generally did not succeed in shrinking, much less eradicating, tumors. The treatment may have had palliative effects but by and large enzymes did not work as anticipated in such books as Saleeby's Conquest of Cancer (1907).
Beard did not deny this, however, he held that since the trophoblastic nature of cancer was irrefutable on theoretical grounds, enzymes would eventually work in the treatment of cancer. It was simply a matter of finding active pharmaceutical preparations and of working out, through practice, the most efficacious route of administering those products. He compared the situation to the early days of North Carolina minister and grew up in the suburbs of New York City. He had a life-long affiliation with homeopathic medicine, which then was at the pinnacle of its influence in America. McDuffie graduated from the New York Homeopathic Medical College in 1904 and served his internship and residency at Flower Hospital, New York, where he later taught gynecology and anatomy. From 1926 to 1927, he was president of the Homeopathic Medical Society of New York. 3 He and his wife, Wilhelmina (née Helmer) were married in 1908 and lived with two sons on West 81st Street in Manhattan.
McDuffie died suddenly in July 1945, while observing a surgical operation at the Polyclinic on West 15th Street. 4 He was 63 years old. Such is the outline of his biography, but little is known about his actual use of intravenous enzymes, especially the clinical results.
Frank LeForest Morse, MD
Shortly after Beard's death, another American doctor, the St Louis, Missouri, physician Frank LeForest Morse, MD (1876 -1953 independently began to use pancreatic enzyme injections in the treatment of cancer. It may be of interest to trace the details of the brief controversy that he caused.
Morse was born in Savanna, Illinois on December 22, 1876. After graduating from high school in 1895, he attended the Beaumont Hospital Medical College in St Louis, Missouri (now St Louis University Medical School) and in 1900 interned at the City Hospital in St Louis. Morse and his wife, Ellen, had one daughter, born in 1904, and one son, who died in childhood. A tall man with red hair and blue eyes, Morse maintained a general practice in downtown St Louis and was also chair of the gynecology department at the College of Physicians and Surgeons of St Louis. For half a century he was a member of the St Louis Medical Society.
Eschewing commercial enzyme products (which Beard also believed were unreliable), Morse made his own fresh extracts from pancreases that he obtained from local slaughterhouses-a messy but potentially effective process. After a decade of quiet clinical work, on March 6, 1934 , he presented his results at a meeting of the St Louis Medical Society. Morse tried to tamp down expectations by reporting that there was no rapid resolution in cases of advanced cancer, much less cures, but that after 4 or 5 injections many patients began to feel better, had an increase in strength, weight, and hemoglobin scores. He told his St Louis colleagues that the patients "really look better, but it is usually 3 or 4 months before any changes can be noticed in the size of the growth." 5 Strange processes of repair occur. A large metastatic growth on the parietal portion of the head that included skin and bone disappeared and the hair grew perfectly. Several pathologic fractures of the ribs healed so perfectly that we could not tell at post mortem that they had ever been involved. An x-ray of a spine case that I will show you tonight had only six injections and left the hospital and now refuses to have another x-ray. Another case referred to me was one with an enormous cancer of the bladder and prostate. He was under treatment for 9 months and died of nephritis. Autopsy showed no sign of cancer.
He continued:
I know full well that this plan of treatment is far from perfect, but considering the type of patients, their hopelessness and the fact that the tumors disappear in some and they have been restored to apparent health, justifies this presentation in the hope that further investigation and experiment may develop something worthwhile in the treatment of cancer. I see the urgency of biological laboratory and clinic material sufficient and varied enough so that we can work out a scientific procedure. 5 The editors of the society's medical journal seemed impressed. "About ten percent respond to treatment," they wrote. "Some of the results have been very gratifying considering the hopelessness of the cases in some of which bone metastasis has receded." 6 But at the meeting only one member, the pathologist Hollis N. Allen, MD, spoke in support of Morse. 7 "Any person who has been privileged to follow a few of Dr Morse's cases might well be astonished," he told his colleagues.
Missourians are known for their "show me" attitude, and these doctors certainly lived up to their reputation. Major G. Seelig, MD, director of the Barnard Free Skin and Cancer Hospital in St Louis, which was the largest cancer hospital west of the Mississippi, remarked:
While I heartily agree with Dr Allen when he strikes the note of encouragement, I recoil at the idea of witlessly spreading the hope of a cancer cure, which is implicit in the remarks of Dr Morse this evening. . . . Not one thing that he has said in his presentation clinched the fact that patients he presented tonight are cancer sufferers.
He scoffed, "If these patients are cancer sufferers, I never saw a healthier looking group of examples of that disease in my life." He demanded biopsy material, ignoring the fact that Morse had just assured his colleagues, "I have biopsies on all cases that I mention tonight," and had offered to make these slides available for each and every case. Seelig also accused Morse of being carried away by irrational exuberance, "If I had a fixed notion I had discovered a cure for cancer, I have no doubt that my enthusiasm would lead me beyond the bounds of strictly logical reasoning." Again, he ignored the fact that Morse had explicitly stated that enzymes were not a "cure for cancer, 5 " but "provided control in some otherwise untreatable cases. 5 
"
Next, Cleveland H. Shutt, MD, spoke in the same spirit as Seelig. He warned that the St Louis Medical Society should not commend Morse's treatment, but in fact should not even give "the suspicion of approval" to his proposal. He claimed that the University of Pennsylvania had done "some work with pancreatic extract a number of years ago," but provided no details on this research.
Louis H. Jorstad, MD, then berated Morse for daring to come before the society, I see no reason, no excuse, for presenting work of this type done on patients, which has not been backed by animal experimentation as well as most careful clinical investigation. . . . The literature is full of data emanating from institutions of repute wherein one finds the implication that if anything will cure cancer in human beings it will do it in animals. . . . I think it is very dangerous to present a cure of this type without that kind of investigation.
Finally, Dr William T. Coughlin concluded, "I cannot accept the evidence as any proof whatever of the value of pancreatic extract as a cure." After this series of stinging rebukes from these esteemed doctors, there was no further mention of this treatment in any of the society's publications. Morse 
Franklin Lloyd Shively, MD
The last American doctor to publicly advocate the use of injections of enzyme for cancer was Franklin Lloyd Shively, MD (1887-1971). Shively was born August 24, 1877 in Dayton, Ohio, the son of John Daniel Shively (1860-1933) and Elizabeth Harriet Brubaker Shively (1870-1949). Shively's great grandfather, Christian Shively Jr (1770-1836), had migrated from Switzerland to Montgomery County, Ohio. Among other things, he had a reputation as a bonesetter and healer. The Shively family was well known and well established in western Ohio.
In 1912, at age 25 years, Frank Shively married Letta May Spreng and they had one son, Franklin Jr, (who became a prominent Dayton physician) as well as one daughter, Justine. 8 In 1914 Shively graduated from Northwestern Medical School, Chicago, and began to practice medicine in Dayton, where he remained for the rest of his life. A slender man of medium build, with brown hair and blue eyes, he was an attending surgeon at Dayton's Miami Valley Hospital. He was a student of George Crile, MD, founder of the Cleveland Clinic, and coauthored a textbook with his mentor. 9 At some point in his successful career, Shively discovered the work of John Beard. In 1949 he wrote a letter to the American Cancer Society (ACS), pleading with its leaders to investigate Beard's ideas. They filed the letter away in their unproven methods files, a repository of what the ACS considered disreputable treatments and practitioners. In 1955, Shively began to inject digestive enzymes into patients with advanced cancer. In addition to trypsin, he added other digestive enzymes, such as chymotrypsin, ribonuclease, desoxyribonuclease, and pepsinogen, while lipase and alpha and beta amylase were given orally. Shively called this treatment multiple enzyme therapy, and gave it the trade name Enzar, although he never actually commercialized it. (An enzyme product called Enzar Forte, is still produced by Elder Pharmaceuticals in India.)
Initially, the treatment was given to 13 terminally ill patients, 2 of whom were said to have survived. In 1959, Shively presented a manuscript entitled "Multiple Enzyme Therapy" to the ACS. However, ACS officials summarily dismissed his claims, on the grounds that other treatments were sometimes also employed in these cases, thus making it "impossible to give credit for beneficial results obtained, as Dr Shively does, to the multiple enzyme therapy alone." 10 In 1963, Congress passed the Kefauver-Harris Amendment Act, which, among other things, gave the Food and Drug Administration (FDA) the right to ban any treatment that did not meet stringent standards of safety and efficacy. To continue to use an unproven treatment after this point required an exception from the rule. In March 1964, the FDA ordered Shively to file for a special exemption to continue using pancreatic enzymes in treating cancer, which he did. On April 24, 1964 the special exception was granted.
However, almost exactly 3 months later, on July 28, 1964, the FDA suddenly reversed itself and cancelled his exemption, on the grounds that he had failed to first prove the safety of enzymes through animal experimentation before using it in patients. Shively rejoined that all of his treatments: (a) were given under the supervision of the staff of Miami Valley Hospital; (b) were only administered to terminally ill patients, who had no further therapeutic options; and (c) had already been safely administered to many people for over a decade, thereby negating any need for preliminary animal experiments.
Throughout 1965, the FDA "quibbled" (to quote Senator Edward Long, D-LA) over Shively's lack of animal safety data. However, in January 1966, and again in March of that year, Shively presented the FDA with a proposal by which he would perform the required experiments. Although the estimated cost was $50,000, Shively said that he would raise the money privately to be in full compliance with FDA's requirements. After a 6-month delay the FDA finally replied in August 1966, but continued to raise further objections.
Then, in late 1966, the FDA abruptly banned any further use of intravenous pancreatic enzyme injections in the treatment of advanced cancer. On December 5, 1966, Senator Long discussed Shively's difficulties on the floor of the Senate. 10 However, the FDA's ban was irreversible and so comprehensive that four decades later no one to my knowledge has attempted to establish a practice administering pancreatic enzymes by intravenous injection to cancer patients in the US. It was ironic that the FDA, at this time, banned a number of approaches as "new" treatments (the toxins of William B. Coley were another prominent example) when it fact they were often far older than other accepted treatments. For instance, the enzyme treatment was already more than 60 years old when FDA banned it as a novel and unproven approach. It was unacceptable, nonetheless, because it hailed from a time before clinical trials were used to prove the safety and efficacy of new treatments.
Aside from struggling in private with FDA officials, Dr Shively did nothing publicly to resist this move. This may have been related to the fact that, as a member of the Church of the Brethren, he had been a pacifist in World War I and believed in nonresistance. Unlike others who found themselves in similar difficulties, he did not pursue a political struggle. In fact, I can only find a single newspaper article about either his treatment or his problems with the FDA. 11 Despite the lack of resistance on his part (or perhaps because of it), in 1967, the ACS condemned his treatment as one of its unproven methods of treating cancer. 12 In 1969, Shively self-published Multiple Proteolytic Enzyme Therapy of Cancer and distributed copies free of charge to medical libraries around the world. Multiple Proteolytic Enzyme Therapy of Cancer was essentially a large mimeographed manuscript, published by a Dayton print shop, which contained detailed records on the results of his treatment, including some records of remissions in cases of advanced cancer that had been achieved through administration of his enzyme combination. Not surprisingly, the book made little impact on the medical profession. Franklin Lloyd Shively died in Dayton on August 30, 1971 .
Ernst T. Krebs Sr and Ernst T. Krebs Jr
Enzyme therapy (like alternative cancer treatments in general) tends to attract idiosyncratic nonconformists. Two such free spirited individuals who, unlike Dr Shively, had no compunctions about publicizing their unconventional approaches to cancer were the father and son team of Ernst Theodore Krebs Sr and Ernst Theodore Krebs Jr. Their names are frequently linked with Beard's in the socalled Beard-Krebs Approach to cancer, 13 but in fact the Krebses (whose name means "cancer" in German) differed in substantial ways from Beard. What is more, widespread opposition to some of their other ideas had the unintended effect of bringing John Beard's theories into disrepute among some medical scientists in the United States.
The father of Ernst T. Krebs Sr had emigrated from Germany in the mid-19th century. Ernst Sr was born in California on September 26, 1876, and received his medical degree in the spring of 1903. He thereupon attained a position as county physician and health officer in Bridgeport, California. Located in the Eastern Sierra Mountains, this was one of the most desolate and isolated parts of the American West.
In early April 1906 Krebs Sr not surprisingly tried to escape from his isolated position and took up medical practice in the populous and lucrative city of San Francisco. His timing was poor, for a few weeks later the famous earthquake and fire destroyed much of the city and Krebs once again had to move, this time to Carson City, Nevada. Here he met and married Ida May Green (1888-1948), with whom he had four children, including two sons Ernst Jr and Byron Asa. Both of his boys later collaborated with him in his medical work.
In 1919, Krebs Sr finally moved his family back to the Bay Area and bought a Victorian mansion at 642 Capp Street, in San Francisco's Mission District. He continued to practice there until 1959 and died in January 1970, at age 93.
Krebs Sr was the type of frontier doctor who was ready to try almost any new treatment he heard about. He tried Beard's enzyme treatment but did not have any dramatic results. "I treated a few cases with these enzymes," he later wrote, "but they did not end in a cure; however, some cases seemed to be improved. [However] I was impressed by Beard's trophoblastic thesis, as it seemed to make sense." 14 Krebs' eldest son, Ernst Theodore Jr, was born in Carson City, on May 17, 1911. He received an erratic education. From 1938 to 1941, he studied medicine at Hahnemann Medical College in Philadelphia, without graduating. In 1942 he received a bachelor's degree from the University of Illinois and from then pursued graduate work at the University of California, Berkeley, again without graduating. In later years he was frequently called "doctor" but this was based on an honorary degree from an irregular institution.
Meanwhile, his younger brother Byron Asa Krebs, who was born in Nevada in 1914, graduated from the College of Osteopathic Physicians and Surgeons in Los Angeles in 1948, and later joined his father in his cancer-related activities. In 1962, when the osteopathic and allopathic physicians in California merged, Byron Krebs converted his DO to an MD degree from the California College of Medicine. He was in full-time general practice in San Francisco until his death in September 1971. 15 In 1938, Ernst Jr discovered a copy of John Beard's book, The Enzyme Treatment of Cancer and Its Scientific Basis. 1 Like Frank Shiveley, this discovery profoundly changed his life. In 1942, the Krebses, along with an academic biochemist, Charles Gurchot, PhD (1895 -1980 , founded the John Beard Memorial Foundation in San Francisco. This was basically a paper organization headquartered in the basement of their Capp Street house. Gurchot almost immediately fell out with the Krebses, and there followed lawsuits over ownership of the foundation's name. (The Krebses won the suit.) Judging from an article that Gurchot wrote on the centenary of Beard's birth, he also had ideological differences with the Krebses. He held the view that mutations in somatic cells could lead to cells that expressed a trophoblastic phenotype, 16 whereas the Krebses adhered to a more rigidly Beardian view that cancer arose exclusively from the transformation of germ cell into trophoblast.
Between 1946 and 1950, the Krebses et al, published half a dozen articles and letters putting forward their version of John Beard's trophoblastic theory. During this time they gained access to some of the leading US medical journals. A high point was a lengthy letter in the Journal of the American Medical Association on the pathology of the trophoblast, in which Ernst Jr determined 20 areas of identity between trophoblastic cells and cancer. He concluded, "These data suggest that the trophoblast cell per se is malignant," and he argued, in Beardian fashion, that cancer was a single (or unitary) disease in which individual characteristics were caused by hormonal factors in the microenvironment of the various anatomical sites in which it occurs. 17, 18 In July 1950, Ernst Jr, published what was arguably his most important article, "The Unitarian or Trophoblastic Thesis of Cancer." Over the next four decades he and several coworkers forcefully reiterated many of Beard's theories, arguing that "cancer is trophoblast" growing "in temporal and spatial anomaly." 19, 20 The Krebses (particularly Ernst Jr) thus played an indispensable role in keeping John Beard's name and theory alive, at a time when it was almost completely forgotten in America and elsewhere.
However, like other advocates of the Beardian thesis, Krebs encountered a stubborn refusal of the medical authorities to listen. Initially, he thought it would be a matter of time before his rational arguments would convince doctors of the rightness of these revolutionary theories, but no amount of persuasion had any effect on the vast majority of allopathic doctors. In the process, Krebs became increasingly disillusioned by the limitations of conventional thinking about cancer. By the 1960s, he stopped attempting to publish in the peer-reviewed journals. Instead, he advocated reaching the masses of cancer patients directly through the use of popular books, articles, and agit-prop. For instance, he worked with the journalists Glenn Kittler (1957) , Edward Griffin (1974), and Michael Culbert (1974) on books that advocated the Krebses' version of the trophoblastic theory.
Beardianism thus moved from the fringe of the scientific world into the popular culture, where it found a more receptive audience among some cancer patients. But as Ernst Krebs Jr failed to gain orthodox acceptance for his ideas, he adopted an increasingly strident tone. In the last decades of his life, he spoke of the "trophoblastic fact of cancer," as if there were no longer any scientific controversy over his or Beard's ideas.
What is less known is that the Krebses were actually revising John Beard's thinking on several points. Trypsin (and secondarily, amylase) had been the linchpin of Beard's therapeutic innovation. Reliance on trypsin runs through all of Beard's writings on cancer, so it is startling to realize that there is no mention of enzymes in the 4 papers that the Krebses published between 1946 and 1950.
In some of their writings, the Krebses actively discouraged the use of trypsin, substituting another pancreatic enzyme, chymotrypsin. For instance, in 1949, Krebs Jr coauthored an article with a Pasadena physician, Clifford L. Bartlett, MD (1889-1975), on the subject of the toxemias of pregnancy. In it, they drew a sharp contrast between the efficacy of trypsin and chymotrypsin, stating:
The two chief proteases of the pancreas gland are trypsin and chymotrypsin. Trypsin is too toxic for parenteral use. Crystalline chymotrypsin, however, has proved nontoxic in man when injected in doses as high as 500 milligrams intravenously within the course of one-half hour [italics added].
The word "parenteral," of course, covers intravenous, intramuscular, subcutaneous, and any other nonalimentary administration. During Beard's lifetime, and sporadically afterwards, trypsin, when it was used, was generally administered in a parenteral way, mainly through intramuscular injections. (There was a vogue for intramuscular trypsin injections for various nonmalignant conditions in the 1950s. 21 ) This was how Beard's contemporaries, as well as McDuffie and Morse, had given it.
There is no space in this overview to explore the varying pharmacokinetics of the different routes of enzyme administration, much less, which might be most efficacious for cancer. Although there was a scientific controversy in the postwar era over the safety of parenterally administered trypsin, most commentators considered the intramuscular route to be relatively safe. Gaschler (see below) reported that only 2 out of 53 patients experienced pain at the injection site when given an enzyme mixture, this was readily controlled by adding procaine (2%) to the mixture. 22 In reference to trypsin, Heinrich Wrba, MD (1922 , of the Institute of Cancer Research, University of Vienna, stated that while "the efficiency of this substance is indubitable," 23,24 an overdose "is not possible and side reactions with absolute certainty do not exist." 25 In the 1950s, Irving Innerfield, MD, a professor at New York Medical College, reported that trypsin-in-oil administered intramuscularly was "safe and effective." At the time that Krebs et al, were condemning trypsin as too toxic, it was widely used to treat inflammatory conditions in 20000 patients per month, according to a popular magazine. 26 Thus, the Krebses, who rose to public attention as staunch defenders of Beard's legacy, had in practice abandoned one of the key elements of Beard's therapeutic innovation, the use of trypsin injections in the treatment of cancer. The fact that this wholesale denigration of trypsin came from founders of the John Beard Memorial Foundation led to further misconceptions about Beard's original thinking.
One also must wonder why, if trypsin injections were too toxic for use, Krebs et al did not explore other routes of administration? Instead, they dropped the use of trypsin entirely. At the same time, they became increasingly preoccupied with several putative anti-cancer agents of their own, which became the source of an acrimonious and ongoing debate. For the Krebses, downgrading of trypsin coincided with their advocacy of the use of two substances of their own discovery, pangamic acid, which they dubbed "vitamin B15," and amygdalin, which they similarly termed "vitamin B17," or Laetrile.
Laetrile Controversy
A full discussion of these thorny medical controversies would take us far afield, but a short discussion is unavoidable. The name Laetrile is a portmanteau word derived from a description of its indisputable scientific nomenclature "laevorotatory nitriloside." As every chemist knows, a laevorotatory chemical is an optically active compound that rotates a plane of polarized light in a counterclockwise direction (i.e., relative to an observer looking toward the oncoming source of light). Nitrilosides, which are common plant constituents, do not occur in a purely laevorotatory form in nature. However, the Krebses claimed to have synthesized a pure laevorotatory nitriloside in their laboratory. The claim has been disputed. But if a true Laetrile were ever synthesized de novo, this was emphatically not the product commonly sold to cancer patients under that name. 27 In everyday practice, Laetrile was simply amygdalin, the cyanide-containing glycoside first isolated in 1844, and found in the seeds and kernels of many members of the Rosaceae family. For commercial purposes, amygdalin was, and is, derived from bitter almonds or apricot kernels. In the presence of certain enzymes, amygdalin breaks down into its two constituent chemicals, benzaldehyde and hydrogen cyanide. The Krebses claimed, however, that poisonous cyanide was selectively released at the site of tumors, while normal cells were protected from its damage. It was a bold and original thesis that cancer in general constituted a nutritional deficiency of cyanide-containing glycosides. One of their many followers later pursued this idea to its logical conclusion by publishing a book entitled The Little Cyanide Cookbook. 28 The Krebses claimed that their theory of laevorotatory nitrilosides was a logical extension of John Beard's philosophy. Beard had in fact followed Pasteur's epochal work on tartaric and racemic acids and believed that there was an enzyme produced by cancer cells, which the chemist Eugen Petry had discovered in 1899. 29, 30 Beard named this malignin. 1 He said that malignin was fundamentally opposed in its stereotactic rotation to enzymes that were normally produced by nonmalignant somatic tissues. So the theory of Laetrile did have some of its roots in Beard's later writing.
However, Beard thought that this discovery lent weight to the use of pancreatic enzymes in cancer. In his final papers he reaffirmed the use of trypsin. He never suggested that there was a need for any "extrinsic factor," as the Krebses called the cyanogenic glycosides, to augment or supplant the activity of what they called the "intrinsic factor," chymotrypsin.
Abandoning trypsin as a therapeutic tool and putting Laetrile (and chymotrypsin) in its place, as the Krebses had done, was a direct contradiction to Beard's fundamental thinking on cancer.
Nonetheless, the Krebses' advocacy of Laetrile and pangamic acid brought them considerable notoriety. Laetrile, it was said, could prevent the occurrence of cancer as completely as vitamin C prevented scurvy. Just as vitamin C could treat existing cases of scurvy, so Laetrile could treat existing cancers. Very few medical doctors agreed with them, but those who did, claimed impressive results using Laetrile as part of their therapy. 31 The history of Laetrile is a long and involved one, which we cannot pursue in this paper. In short, after many ups and downs, it was finally subjected to a clinical trial at Mayo Clinic in the 1980s, a test that it failed by all accounts. 32 Whatever its merits or deficiencies, this trial, and the widespread dissemination of its results, led to a steep decline in Laetrile's use. However, it periodically resurfaces creating a recurring source of controversy in the world of cancer therapeutics. 32 Ernst T. Krebs Jr died at his Capp Street home on September 8, 1996. Few individuals in history have been so reviled by mainstream medicine as was Krebs and his father. Yet, whatever their failings, they undoubtedly helped to keep the name and work of John Beard alive and introduced thousands of people to the rudiments of Beard's thinking, thereby helping preserve the trophoblastic theory of cancer for later generations.
Howard H. Beard, PhD
Another member of the Krebses' circle who bears mentioning was Howard Horace Beard, PhD In the early 1930s, Howard Beard became an assistant professor of biochemistry at Case Western Reserve University Medical School, Cleveland, Ohio. He was then appointed as a professor of biochemistry at Chicago Medical School and was also affiliated with Holy Cross Hospital. The high point of his regular academic career came in 1940 when he chaired the New Orleans meeting of the Federation of Societies for Experimental Biology (FASEB), then, as it now is one of the largest biology organizations in the world.
In the 1940s, while still in Chicago, his thinking about cancer began to diverge from his mainstream colleagues. He discovered the work of John Beard and the Krebses, and with the Krebses he coauthored one of their most influential papers, "The Unitarian or Trophoblastic Thesis of Cancer." At this time, Howard Beard began to work on clinical assays for cancer. In 1942, he developed his so-called biological test. In this test, an extract of the patient's urine was injected into young rats. This reputedly determined if the patient had cancer. However, this test took almost a week to run and was both inefficient and expensive.
In the 1950s, as Director of the Beard Biochemical Laboratory in Fort Worth, Texas, he developed what he called his so-called milk test. This was based on the alleged slower curdling speed of milk in the presence of urine from cancer patients. 34 This test was also less expensive than his first test and took only a few hours to run. Although he claimed the new test was more than 95% accurate, he was still dissatisfied with the possibility of human fallibility in its performance.
In 1958, which was the centenary of John Beard's birth, Howard Beard published A New Approach to the Conquest of Cancer, Rheumatic and Heart Diseases, dedicated to the memory of the earlier Beard. This was the first popular exposition of John Beard's ideas for the American public in half a century (ie, since the publication of C. W. Saleeby's Conquest of Cancer in 1907). The book was widely distributed through natural food stores for many years. Finally, in 1953, Howard Beard developed a colorimetric assay that he called the Beard anthrone test of the urine for cancer. An anthrone is a tricyclic aromatic hydrocarbon, which forms the basis of a spectronic or colorimetric determination of various chemicals. Beard now claimed an even greater degree of accuracy than with the previous two assays. "These tests are based upon the trophoblastic thesis of malignancy," Howard Beard wrote, "and thus show its validity." 35 In his final years, Howard Beard held a succession of jobs including: a chemist at the T. C. Terrell Laboratories, Fort Worth, Texas; a clinical biochemist at the Harris Clinic, Sherman Oaks, California; and a director of his own John Beard Laboratory of Clinical Biochemistry in Hollywood, California. He died in Sequoyah, Oklahoma, in May 1978, at age 84.
He was one of the few conventionally trained scientists of any prominence to be associated with the Laetrile phenomenon. Other than making an occasional reference to chymotrypsin, however, he also abandoned the focus on the therapeutic potential of pancreatic enzymes, especially trypsin.
William Donald Kelley, DDS
William Donald Kelley, DDS (1925 was arguably the most famous practitioner of enzyme therapy in US history. Coming after the time that the FDA banned the parenteral use of enzymes, Kelley advocated massive amounts of pancreatin taken orally. This became the centerpiece of a very unconventional cancer treatment protocol.
A full discussion of Kelley's philosophy is beyond the scope of this article, however it is necessary to discuss somewhat the acrimonious debate that has surrounded his work and ideas.
Kelley's great, great grandfather, Lachlan Kelley, arrived in Philadelphia in 1850, following the Irish potato famine. His father, William Butler Kelley (1904 Kelley ( -1954 , was born in Oklahoma but worked in southern Kansas as a machinist for the Santa Fe railroad. Kelley Kelley was already experimenting with the anthrone test, "studying and researching the details of cancer" at the time that he became ill. 36 Whether or not Kelley ever actually had cancer is an important question in his biography. In 1964, after a "long, long period of horrible depression," he later said, he developed acute gastric distention and visited a local internist. After a 3-month period of conventional diagnostic testing, his doctor suggested a series of biopsies.
"This was quite a shock to me," Kelley later wrote, "and it then dawned on me the true condition of my body." 36 Based on various amorphous symptoms, but without a definitive biopsy, Kelley concluded that, in fact, he had pancreatic cancer. "I had undergone many other tests and diagnostic procedures including x-rays, when the internist suggested biopsies of my pancreas, liver, and intestines. He suspected that these operations would reveal cancer. Although the biopsies were not performed, the physician's suspicions were correct." 37 "By this time," Kelley added, "I had found a very reliable biochemical test for the early detection of cancer," ie, Howard Beard's anthrone test. Kelley performed the Beard anthrone test on himself and the results seemed to indicate cancer. "Then I decided to run our biochemical test on my own family. The results were deeply shocking," he wrote. "My wife, 2 of my 3 children, and my mother had cancer, also." 37 Howard Beard's anthrone test was highly experimental. For a variety of reasons, it was prone to false positive and negative results. A sensible person would not base a cancer diagnosis on such an unreliable assay. In addition, confronted by such an implausible finding as cancer in an entire family, most people would question the validity of the test. (The odds of a child developing cancer before age 20 are approximately 1 in 300. 37 The chance of 2 children, as well as both parents and a grandparent, all being simultaneously afflicted with cancer is thus infinitesimally small.) Kelley never doubted the accuracy of the unconventional anthrone test. Instead, in the absence of more definitive proof, he concluded that he and nearly everyone in his family was afflicted with cancer, even in the absence of clinical signs or symptoms of the disease in most of his relatives.
Kelley went beyond anything Howard Beard claimed, stating that the anthrone test could predict with absolute precision when he, or any other person, first developed cancer, and when they were scheduled to die. "I had cancer 3 years and 7 months before it ever dawned on me," he later wrote, "At the height of the cancer I had only 3 weeks and 5 days to live." 37 Common sense would dictate that no test then, now, or in the future, could specify the course of cancer in such accurate detail. According to Kelley, My wife was privately told not only that I had tumors in all 3 organs [the pancreas, liver, and intestines], but also that in the doctor's opinion I had no more than 18 months to live. . . . Meanwhile, the chief surgeon in our locale had ruled out full-scale surgery because he thought I was in such bad shape that I wouldn't make it off the operating table alive. My wife had been told to take me home and get our affairs in order as promptly as possible, for it wouldn't be long before I'd passed away. 37 Assuming this was an accurate representation of the doctors' opinions, it was made in the absence of definitive biopsies, which Kelley had rejected.
The prospect of having terminal cancer-even in the absence of definitive proof-may have exacerbated a preexisting area of mental instability. By his own admission, Kelley was prone to deep depression and became overwhelmed by "fear and despair." He now said he had "firsthand insight into that horror of horrors," a diagnosis of advanced cancer. He thereupon reinterpreted the multitudinous symptoms of the previous years as proof of his alleged malignancy:
The cancer had eaten into the nerve connections to my heart, causing rapid pulse rates and irregular beating. My cancerous pancreas was so damaged and enlarged that I had hypoglycemia and was going into insulin shock several times a day. My liver also was cancerous and enlarged. I could not eat much, as I was so nauseated. My intestines were so laden with cancer that I was in constant pain. 37 It is a terrifying picture, complete except for the proof that he was in fact suffering from any sort of malignancy. The symptoms he describes could more plausibly be attributed to less drastic causes. Nonetheless, he began to treat himself for this supposedly terminal cancer. He ransacked books and pamphlets for ideas. A major element in his improvised program was the ingestion of a large number of pancreatic enzymes-72 or more capsules per day, taken at 4-hour intervals, away from meals.
At this time, Kelley was influenced by the work of Edward Howell (1898-1988) , author of The Status of Food Enzymes in Digestion and Metabolism and an early advocate of raw food consumption. 38, 39 Howell believed that enzymes that are normally present in uncooked food added significantly to the digestion of the foods themselves. Cooking, Howell said, destroyed these enzymes, thereby forcing the body to produce more of its own digestive enzymes than might otherwise be necessary. Howell further claimed that the length of life of an organism is inversely proportional to the rate of exhaustion of its enzyme potential.
After following his improvised program for some months, Kelley began to feel better, and his diverse symptoms abated. Rumor spread in well-named Grapevine that a local orthodontist had cured himself of metastatic pancreatic cancer through dietary manipulation. It was not long before cancer patients started arriving at Kelley's door, imploring him to do for them what he had apparently done for himself. At times, he later told me, the line of patients snaked, Lourdes-like, around the block.
In response to this outpouring of public interest, in 1969 he published a 38-page pamphlet, One Answer to Cancer: An Ecological Approach to the Successful Treatment of Malignancy. His treatment, which he now called the Kelley Nutritional-Metabolic Cancer Program, became a nationwide phenomenon. The pamphlet went through 13 printings and, according to the jacket copy, sold more than 150,000 copies. Kelley's personal conquest of cancer was the foundation stone of his method's appeal and in time became an article of faith among a growing number of followers.
The Dallas-Fort Worth International Airport opened in Grapevine in 1974. Henceforth, it became relatively easy for cancer patients to fly in from other locations to see the cancer-treating orthodontist. In time, however, the relevant health authorities became concerned about this phenomenon on their doorstep and began to closely scrutinize his activities. Undercover agents arrived with the purpose of catching him in the act of illegally practicing medicine. Eventually, Kelley performed his functional metabolic test and provided medical advice to two federal agents. One of whom named Albert Crites, later testified in court that Kelley had told him he had a pancreatic insufficiency. Another, John Sortore, testified that Kelley diagnosed him as having benign hyperplasia of the prostate.
According to the federal agents, Kelley further claimed that if they took recommended dietary supplements their conditions would improve. Today, this hardly seems like a damning indictment, when many urologists routinely advocate the use of omega-3 fish oil supplements, saw palmetto, and other herbs and nutrients for the prevention and even treatment of prostate diseases. But in 1970, such ideas were highly controversial. As the result of a suit brought by the Texas State Board of Medical Examiners, Kelley was permanently enjoined from treating all non-dental diseases. There were a total of 27 findings of the court. In essence, they concluded that Kelley was in violation of Article 4510 of the Texas Medical Practice Act, ie, that he was practicing medicine without the required license.
More controversially, Kelley was also prohibited from distributing his One Answer to Cancer pamphlet, either locally or nationally. The state charged in effect that the pamphlet was not medical literature per se but simply advertising, and that Kelley was therefore disseminating promotional material to "control, curb, or cure certain diseases and disorders for a charge." 40 Even more questionably, the court held that "following the regime in the book could be harmful and detrimental to the body," 40 which implies that the accuracy of health information, in the judgment of a majority of doctors, had become a requirement for one's right to publish at all. In his defense, Kelley argued that it was "absolutely impossible to practice medicine by the publication and distribution of a book," and that suppressing the pamphlet would abrogate fundamental constitutional freedoms of press and speech. But in May 1971, this verdict was upheld by the state's Appellate Division. 40 The appeals court held that since the purchase price of One Answer to Cancer was sometimes paid indirectly as part of the fee for his examination and blood test, it thereby constituted advertising for Kelley's treatment.
In alarmist language, the court claimed:
The continued distribution of the book, directly or indirectly by the defendants, would constitute a grave, immediate threat of irreparable harm, a clear and present danger of physical, or mental injury or harm to the general public. . . . Constitutional rights of speech and publication are not absolute and in a given case where the public interest is involved, courts are entitled to strike a balance between fundamental constitutional freedom and the State's interest in the welfare of its citizens. The constitutional guarantee of freedom of expression must yield in the case at bar to afford reasonable protection to the public. 40
How an obscure dentist practicing nutritional medicine in Grapevine, Texas, constituted a "grave and immediate threat of irreparable harm" and a "clear and present danger" to the state of Texas is puzzling. But the US Supreme Court, with Justice William O. Douglas dissenting, refused to review the case. This ruling did not stop Kelley, but it did help to muzzle nonconventional medical practice in Texas and beyond.
His trial and protracted appeals process was the source of a great deal of personal stress for Kelley Kelley's protocol was very demanding, however, requiring the intake of more than 100 dietary supplements per day. McQueen refused to follow this program consistently, although he was said to be feeling better than expected.
On November 6, 1980, surgeons in Mexico removed some masses from McQueen's neck and abdomen, but he died on the following day. Despite the fact that his death was almost certainly because of complications of surgery, the mainstream media drew the conclusion that Kelley's program was somehow responsible, and had thereby been proven ineffective, or may even have accelerated the death of the unfortunate actor.
The McQueen case precipitated a downward spiral for Kelley. Amidst the uproar, his third marriage ended in divorce. One bright spot of the 1980s was that Fred Rohé, who owned natural food stores in the San Francisco area, published a book on Kelley, Metabolic Ecology: A Way to Win the Cancer War. Bound together with One Answer to Cancer (with certain portions grayed out) these books brought Kelley's message to a wider audience, mostly customers of natural foods and nutritional supplements.
Another high point in the 1980s was that Kelley's treatment came to the attention of a Cornell University medical student named Nicholas J. Gonzalez. Through him, Kelley also came to the attention of Robert A. Good, MD, PhD, president of Sloan-Kettering Institute, New York. This did not result in any publication, but it was as close as Kelley ever came to a serious evaluation of his work.
In the late 1980s, Kelley began a precipitous physical and mental decline. For several years his whereabouts were unknown even to former friends and colleagues. In 1990, I learned from a patient that Kelley was living in Saxonburg, Pennsylvania, an hour northeast of Pittsburgh. I visited him twice that spring and summer, at the small bungalow on Water Street that he shared with a companion, Carol A. Morrison, MD. Dr Morrison was a Philadelphia cardiologist, who claimed to have been cured of advanced breast cancer by following Kelley's nutritional program.
Both Kelley and Morrison had by then largely both turned their backs on medicine. They had an almost frenetic energy, however, in churning out pseudo-religious tracts and delivering these by mail to various individuals (including myself). These writings were filled with anti-Semitic and racist ravings of the vilest kind. It was difficult to reconcile the Kelley that I got to know in 1990 with the kind and caring individual described by others who knew him in earlier decades.
After 41 The large movement that Kelley once organized to promote his treatment philosophy has dwindled, although a few practitioners, most notably Nicholas Gonzalez, MD, and a nutritionally oriented chiropractor, Jack Taylor, DC, persisted in using Kelley's methods, including large doses of oral enzymes.
Nicholas J. Gonzalez, MD
Since the breakup of Dr Kelley's project, a few practitioners have attempted to continue his treatment concept. One of these is Nicholas James Gonzalez, MD, of New York. While a medical student at the Weill Medical College of Cornell University, he developed an interest in Dr Kelley's claims. He obtained, as his study advisor, Robert A. Good, MD, PhD, president of Sloan-Kettering Institute.
Over the next few years, he completed a laborious evaluation of Dr Kelley's cases, although this manuscript was never published. In 1993, an official of the National Institutes of Health invited Gonzalez to present select cases from his practice. Gonzalez subsequently published a pilot study of 10 patients with stages 2 to 4 pancreatic cancer who were treated with an aggressive nutritional protocol, including oral pancreatic enzymes. 42 According to a December 1999 statement from the NIH, "patients on the Gonzalez regimen lived an average of 17 and a half months, which is nearly 3 times the usual survival period for patients with advanced pancreatic cancer." 43 As a result of these promising preliminary results, NIH funded a randomized clinical trial of the method at Columbia-Presbyterian Hospital, New York, with a grant of $1.4 million. Because of low rates of accrual, this was changed into a case-cohort study. In 2005, however, Dr Gonzalez raised concerns to trial administrators about the manner in which Columbia University was conducting the trial. In 2006, Columbia and NIH suspended recruitment into this case-cohort trial. It now appears that this once promising investigation will not be able to resolve the long-standing issue of whether or not oral enzyme therapy positively impacts the outcome of pancreatic cancer in human patients.
European Developments
So far, this article has discussed only American developments in enzyme therapy. But there was a parallel development of enzyme therapy in Europe, particularly in Germany. For Europeans, however, the "father of systemic enzyme therapy" was none of the above figures, not even John Beard, but Max Wolf, MD (1885 -1976 . More than any other individual, Wolf made enzyme therapy a household concept to thousands of medical consumers around the world.
This was not a purely European development, however. Wolf was born in Vienna in 1885, became a naturalized American citizen, and developed his distinctive products in New York City. Nonetheless, his major impact was felt in central Europe.
Max Wolf received his undergraduate education at the University of Vienna and was in New York in August 1914, visiting his brother, William, when World War I broke out. Wolf tried to return to his homeland, but was unable to do so because of the war. Max therefore settled in New York, and he and William simultaneously received medical degrees from Fordham University in 1919. Max Wolf continued his affiliation with Fordham for many years.
In the 1920s and early 1930s, Wolf frequently returned to Vienna, where he studied with two prominent cancer researchers at the Rudolfina Hospital, Professor Ernst Freund (1863-1946), and his long-time associate, Dr Gisa Kaminer (1883-1941). One aspect of their work was elucidation of a factor in the blood of cancer patients that seemingly allowed tumors to grow. They believed that this factor could be overcome by the administration of enzymes. Freund also advocated a largely vegetarian diet for cancer patients.
Through his interest in classical music, Max Wolf was appointed as the official physician of the Metropolitan Opera and had an increasingly successful "white glove" medical practice on New York's Upper East Side. His roster of patients included famous musicians such as Enrico Caruso, Wilhelm Furtwängler, and Arturo Toscanini, and Hollywood celebrities such as Marilyn Monroe and Clark Gable, and eventually politicians such as John Foster Dulles and John Kennedy.
Most of these luminaries were treated with intramuscular enzyme injections, usually for various inflammatory conditions. In the days before NSAIDs, such injections were a popular feature of the American medical scene. Wolf was considered a medical wonder worker by his celebrity patients.
Wolf was also influenced by the work of Adolf Gaschler, MD, who even during World War II researched enzyme therapy at Berlin's Charité hospital, under a grant from the German Research Organization (Deutsche Forschungsgemeinschaft). 44 Gaschler developed a formula called Carzodelan, whose main ingredient was a trypsin-like compound capable, he said, of dissolving tumoral protein.
Carzodelan was administered by intramuscular injections averaging 3 times per week for 6 weeks, followed by 2 times per week for an indefinite period. 45 In the 1930s, Gaschler and his wife, Sophie, distributed Carzodelan through their own company, Pharma Laboratorium, in Landshut, Bavaria. After the war, he published a book on the parenteral enzyme therapy of malignant tumors and chronic inflammation conditions. 46, 47 Before he developed his own oral formulas in the 1950s, Max Wolf also used Carzodelan in his New York practice.
In the 1950s, with the support of US Secretary of State John Foster Dulles, Wolf established an institute for cancer research in New York. He hired Helen Benitez, formerly a researcher in Columbia's Department of Anatomy, to isolate and purify enzymes of both animal and vegetable origin. Together, they developed two enzyme mixtures, one for cancer, the other for inflammation, which were launched commercially in the late 1950s. The innovation was that such enzymes-until then generally given by injection-were repackaged as an oral preparation, suitable for mass marketing as food supplements for a broader audience of supplement consumers.
Wolf and Benitez last names were shortened and melded to become WoBe, a name that is memorialized in a celebrated German product, Wobenzym N. This supplement contains proteolytic enzymes from fractionated hydrolysates of beef pancreas, but also from calf thymus, pisum sativum (peas), lens esculenta (lentils), and immature papaya carica (papaya).
Wolf also paid homage to John Beard by translating his book, The Enzyme Treatment for Cancer, into German, the only foreign translation to date. In the early 1950s, a graduate student named Karl Ransberger (1929-2001) became Wolf 's protégé at Fordham University, from which he received a doctorate in 1957. Ransberger had come to the US in July 1950, after postwar restrictions on German travel were lifted. In 1957, he returned to Germany, where he took over administration of a small Munich pharmaceutical company. He introduced Wobe-Mugos enzymes to Spain (1958) , Germany (1960), and other European countries. In 1963, the German health authorities approved distribution of Wobe-Mugos enzymes (alternately spelled Wobe-Mucos), according to the company Web site. 48 Wolf 's ingenuity, Benitez's laboratory skill, and Ransberger's business acumen turned out to be a winning combination. Wobe-Mugos and a subsequent product, Wobenzym N, became best-selling enzyme formulations, particularly popular as anti-inflammatory supplements for German athletes. It consists of entericcoated tablets containing pancreatin, papain, bromelain, trypsin, chymotrypsin, and rutin. Through the sale of these products, Ransberger became a wealthy man and funded basic research into enzymes and other natural products. 49 Ransberger died in 2001. In July 2007 his company was sold to Québec-based Atrium Innovations, Inc, for 127.5 million. For various reasons, Wobe-Mugos has been phased out, but Wobenzym N is still popular for its anti-inflammatory action.
Current Situation
With funds from the sale of Wobe-Mucos, Karl Ransberger brought research on enzyme therapy to European academia. Mainly because of him, pancreatic enzymes became a respectable research topic, especially in Europe and Asia. Elsewhere in this issue, there are articles by some of these European researchers. Here, in brief, are some other examples of recent academic research on the therapeutic use of oral enzymes.
1995.
Eva Závadová et al, then of University of Vienna, showed that Wobenzym increased the time-dependent release of reactive oxygen species (ROS) from polymorphonuclear neutrophils (PMN). The release of ROS is considered one of the ways in which the immune system destroys cancer cells. In contrast, ROS production was not elevated in the PMN of healthy volunteers that were mixed with placebo or nontreatment. "These findings point to an immunomodulatory capacity of Wobenzym in adjuvant tumor therapy," she wrote. 50 1999. R. Kaul et al, of the SGPT Cancer Hospital, Indore, India, showed that Wobe-Mucos oral enzymes acted as potent anti-inflammatory and antiedematous agents, thereby decreasing acute toxic effects of radiation and increasing compliance and quality of life of cancer patients. 51 2001. M. S. Gujral et al, Indore, India, showed that enzymes could prevent radiation-induced side effects in patients with head and neck cancer. One hundred patients received gamma radiation at a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6 to 7 weeks. Patients assigned to the test group arm received enzyme tablets orally 3 times a day, starting 3 days prior to radiation therapy, and continuing up to 5 days after completion of the course of radiation therapy. A control group did not receive enzymes. The severity of acute radiation therapy side effects was significantly lessened in enzyme-treated patients than in control patients. 52 2001. Adriena Sakalova et al, of the University of Bratislava, Slovakia, tested an oral enzyme (OE) preparation in patients with multiple myeloma.
Significantly higher overall response rates and longer duration of remissions were observed in the OE-group. Primary responders showed a longer mean survival time than nonresponders. Additive therapy with OE given for more than 6 months decreased the hazard of death for patients at all stages of disease by approximately 60%. 53 In stage 3 patients, median survival was 47 months in the control group versus 83 months for the patients treated with OE, for a 3-year gain. 53 2001. Prakash S. Dale et al, Maharashtra, India, tested the effects of radiation therapy in a prospective randomized controlled trial (RCT) of 120 patients with stages 2a, 2b, or 3b carcinomas of the uterine cervix. Patients all received 50 Gy of external radiation therapy over a period of 5 weeks, followed by intracavitary brachytherapy (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . The test group (60 patients) also received treatment with orally administered digestive enzymes. The authors concluded: "In patients with locally advanced cancer of the uterine cervix, oral enzyme therapy was found to be effective in significantly reducing radiation therapy-related side effects such as genitourinary symptoms, subcutaneous changes, and reactions of the vaginal mucosa. 
Conclusions
In central Europe, India, and other parts of the globe, the use of pancreatic enzymes as an adjuvant treatment for cancer has become fairly routine practice, at least among doctors who utilize CAM. It is also a well-established method for reducing inflammation and mitigating the adverse effects of cytotoxic treatment. But in the Englishspeaking world, particularly the US, the use of pancreatic enzymes remains controversial and has followed a more difficult trajectory. Claims for enzyme therapy have often been grandiose, and the opposition to the use of enzyme therapy has been commensurately more determined.
The careers of Drs Morse, Shively, and Kelley each, in its own way, illustrates the contentiousness that has sprung up around any treatment that purports to be a valid alternative to conventional approaches. In the case of Morse, for instance, the claims from this distance seem modest, but nevertheless the reaction was robust. This polarization has created an atmosphere not of cooperation but of intense competitiveness, in which each side has generally excoriated the other.
On the other hand, in some countries, such as Germany and India, enzymes have found a more receptive environment. Here, for historical reasons, the gap between private practice and academic research is not as great, and it has been possible to build up a base of scientific studies, which support the continued use of digestive enzymes.
In the course of almost a dozen exploratory trips, I have met no one in Europe who believes that enzymes are "the cure for cancer," the way that Dr Kelley and some of his disciples enthusiastically claimed. Nonetheless, European practitioners have managed to establish a therapeutic legitimacy for the use of enzymes in medical practice that is almost entirely lacking in the US. This, too, is the legacy of John Beard.
